Your email has been successfully added to our mailing list.

×
0.107207207207207 0.107207207207207 0.107207207207207 0.107207207207207 0.107207207207207 0.0558558558558559 0.0603603603603604 0.0513513513513514
Stock impact report

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Oncology SA - American Depositary Shares (CYAD) 
US:NASDAQ Investor Relations: celyad.com/en/investors
Company Research Source: Business Wire
Preliminary data from the Phase 1 CYCLE-1 trial are expected during second half 2020 MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News:Celyad (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the successful administration of the next-generation, NKG2D-based candidate CYAD-02 to a relapsed/refractory acute myeloid leukemia (r/r AML) patient enrolled in the Phase 1 CYCLE-1 trial.Dr. Dries Deeren, Head of Clinical Hematology at AZ Delta Hospital Roeselare said, “We are proud to be participating in the CYCLE-1 trial evaluating the novel CAR-T cell therapy, CYAD-02, for the treatment of patients with advanced acute myeloid leukemia. Initial clinical results from Celyad’s AML and MDS program look encouraging. Based on preclinical data, where CYAD-02 has shown a differentiated and more potent profile to the first-generat Show less Read more
Impact Snapshot
Event Time:
CYAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CYAD alerts
Opt-in for
CYAD alerts

from News Quantified
Opt-in for
CYAD alerts

from News Quantified